Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 4
1995 3
1996 6
1997 1
1998 7
1999 9
2000 18
2001 20
2002 18
2003 13
2004 12
2005 26
2006 33
2007 26
2008 34
2009 34
2010 44
2011 62
2012 75
2013 87
2014 91
2015 108
2016 104
2017 131
2018 158
2019 145
2020 165
2021 199
2022 209
2023 191
2024 149

Search Results

1,914 results

Results by year

Filters applied: . Clear all
Page 1
Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
Dong L, Lu D, Chen R, Lin Y, Zhu H, Zhang Z, Cai S, Cui P, Song G, Rao D, Yi X, Wu Y, Song N, Liu F, Zou Y, Zhang S, Zhang X, Wang X, Qiu S, Zhou J, Wang S, Zhang X, Shi Y, Figeys D, Ding L, Wang P, Zhang B, Rodriguez H, Gao Q, Gao D, Zhou H, Fan J. Dong L, et al. Cancer Cell. 2022 Jan 10;40(1):70-87.e15. doi: 10.1016/j.ccell.2021.12.006. Epub 2021 Dec 30. Cancer Cell. 2022. PMID: 34971568 Free article.
Proteogenomic characterization of cholangiocarcinoma.
Deng M, Ran P, Chen L, Wang Y, Yu Z, Cai K, Feng J, Qin Z, Yin Y, Tan S, Liu Y, Xu C, Shi G, Ji Y, Zhao JY, Zhou J, Fan J, Hou Y, Ding C. Deng M, et al. Hepatology. 2023 Feb 1;77(2):411-429. doi: 10.1002/hep.32624. Epub 2022 Jul 5. Hepatology. 2023. PMID: 35716043 Free PMC article.
Cholangiocarcinoma.
Krasinskas AM. Krasinskas AM. Surg Pathol Clin. 2018 Jun;11(2):403-429. doi: 10.1016/j.path.2018.02.005. Surg Pathol Clin. 2018. PMID: 29751883 Review.
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
Subbiah V, Sahai V, Maglic D, Bruderek K, Touré BB, Zhao S, Valverde R, O'Hearn PJ, Moustakas DT, Schönherr H, Gerami-Moayed N, Taylor AM, Hudson BM, Houde DJ, Pal D, Foster L, Gunaydin H, Ayaz P, Sharon DA, Goyal L, Schram AM, Kamath S, Sherwin CA, Schmidt-Kittler O, Jen KY, Ricard F, Wolf BB, Shaw DE, Bergstrom DA, Watters J, Casaletto JB. Subbiah V, et al. Cancer Discov. 2023 Sep 6;13(9):2012-2031. doi: 10.1158/2159-8290.CD-23-0475. Cancer Discov. 2023. PMID: 37270847 Free PMC article.
1,914 results